Juvena Therapeutics Patents

Patent portfolio assigned to Juvena Therapeutics (verified via public assignee records). Estimated patent count: 4. Clinical-stage regenerative-biologics company (founded 2017); raised $33.5M Series B Jan 2026. Google Patents shows Juvena Therapeutics Inc. as original assignee on multiple filings (heparin-associated and regenerative polypeptides), e.g. US10821155B2, US20240294597A1, EP4606428A3. No named customers (drug developer). Competitor lists only found on aggregators, not used.